Treatment of familial exudative vitreoretinopathy through S1PR2 inhibition

Patent metadata

Field	Value
Publication number	US-10058543-B2
Application number	US-201515316072-A
Country	US
Kind code	B2
Filing date	Jun 1, 2015
Priority date	Jun 2, 2014
Publication date	Aug 28, 2018
Grant date	Aug 28, 2018

Abstract

Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) and retinopathy of prematurity (ROP) through the administration of a therapeutically effective amount of a Sphingosine-1-phosphate receptor type 2 (S1PR2) inhibitor.

First claim

The invention claimed is:

1. A method of treating familial exudative vitreoretinopathy in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (II):

wherein,
Ar 1 is pyridine, which is optionally substituted;
W is —NR a —, wherein R a is independently selected from hydrogen and C 1 -C 3 alkyl;
Z is C(═O)—;
Y is —NR a —, wherein R a is independently selected from hydrogen and C 1 -C 3 alkyl;
X is —CH 2 —;
R 1 is C 1 -C 12 alkyl;
R 2 , R 3 , and R 4 are each independently hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 perhaloalkyl, C 1 -C 4 perhaloalkoxy, amino, mono- or di-C 1 -C 4 alkylamino, C 3 -C 7 cycloalkyl, or C 3 -C 7 cycloalkyloxy, wherein R 3 and R 4 can be positioned at h, i, or j, but not simultaneously at the same position; and
X 2 in both cases is N.

2. The method of claim 1 , wherein the compound is

3. The method of claim 1 , wherein the compound is

4. The method of claim 1 , wherein the compound is

Assignees

• Univ Dalhousie

Inventors

• Mcmaster Christopher

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K31/505

  Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title